RESPIRATORY INFECTIONS: Edited by Michael S. NiedermanNew antifungal antibioticsPaiva, José A.; Pereira, José M.Author Information Emergency and Intensive Care Department, Centro Hospitalar S. João, EPE, Faculdade de Medicina, University of Porto, Infection and Sepsis Group, Porto, Portugal Correspondence to José A. Paiva, Emergency and Intensive Care Department, Centro Hospitalar S. João, EPE, Al Prof Hernâni Monteiro, 4200–319 Porto, Portugal. Tel: +351 913 899 800; e-mail: [email protected] Current Opinion in Infectious Diseases: April 2013 - Volume 26 - Issue 2 - p 168-174 doi: 10.1097/QCO.0b013e32835ebcb7 Buy Metrics Abstract Purpose of review The incidence of both invasive fungal infections and respiratory mould infections is increasing and they cause significant costs, morbidity and mortality. Non-Aspergillus moulds are increasing as cause of lung infections in specific populations and new problems of susceptibility and resistance are appearing. Recent findings The antifungal armamentarium has markedly improved in the past 10 years and some new drugs are in the pipeline. The use of these new agents is one of the drivers of the changes in fungal epidemiology. These new antifungal drugs are discussed in this article. Summary A good selection of the antifungal, taking into consideration the pathogen, the host and the pharmacokinetic/pharmacodynamics of the drug, is paramount for clinical success. Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.